MR imaging versus PET/CT for evaluation of pancreatic lesions

Belião, Sara; Ferreira, Alexandra; Vierasu, Irina; Blocklet, Didier; Goldman, Serge; Metens, Thierry; Matos, Celso

doi:10.1016/j.ejrad.2011.11.045

Cited by 9 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This volume is 2600 to 6200 times smaller than the current limits of tomographic imaging (6-8 mm in diameter). 3,4,6 A larger tumor would have a higher rate of ZsGreen production and would be detectable earlier (Fig. 6B).…”

Section: Discussionmentioning

confidence: 94%

“…This volume is 2,600 to 6,200 times smaller than the current limits of tomographic imaging (6–8 mm in diameter). 3,4,6 A larger tumor would have a higher rate of ZsGreen production and would be detectable earlier (Figure 6B). A larger tumor would support a greater number of bacteria, which would, in turn, produce more ZsGreen.…”

Section: Discussionmentioning

confidence: 97%

“…2,3 These techniques lack the spatial resolution needed to detect tumors and metastases less than 6-8 millimeters in diameter. [3][4][5][6][7][8][9][10] Endogenous biomarkers can be used in conjunction with imaging techniques to identify cancer, but they are sub-type specific and highly variable. 11,12 The biomarker concentration threshold, at which a reading is considered abnormal, is difficult to determine because expression from normal tissue can vary from patient to patient.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Genetically modified bacteria as a tool to detect microscopic solid tumor masses with triggered release of a recombinant biomarker

Panteli

Forkus

Dessel

et al. 2015

Integrative Biology

View full text Add to dashboard Cite

Current tomographic methods of cancer detection have limited sensitivity and are unable to detect malignant masses smaller than half a centimeter in diameter. Mortality from tumor recurrence and metastatic disease would be reduced if small lesions could be detected earlier. To overcome this limitation, we created a detection system that combines the specificity of tumor-targeting bacteria with the sensitivity of a synthetic biomarker. Bacteria, specifically Salmonella, preferentially accumulate in tumors and microscopic metastases as small as five cell layers thick. To create tumor detecting bacteria, an attenuated strain of Salmonella was engineered to express and release the fluorescent protein ZsGreen. A single-layer antibody method was developed to measure low concentrations of ZsGreen. Engineered bacteria were administered to a microfluidic tumor-on-a-chip device to measure protein production. In culture, half of produced ZsGreen was released by viable bacteria at a rate of 87.6 fg·bacterium−1·h−1. Single-layer antibody dots were able to detect bacterially produced ZsGreen at concentrations down to 4.5 ng/ml. Bacteria colonized in 0.12 mm3 of tumor tissue in the microfluidic device released ZsGreen at a rate of 23.9 μg/h. This release demonstrates that ZsGreen readily diffuses through tissue and accumulates at detectable concentrations. Based on a mathematical pharmacokinetic model, the measured rate of release would enable detection of 0.043 mm3 tumor masses, which is 2,600 times smaller than the current limit of tomographic techniques. Tumor-detecting bacteria would provide a sensitive, minimally invasive method to detect tumor recurrence, monitor treatment efficacy, and identify the onset of metastatic disease.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 97%